Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Clinical Pharmacology and Therapeutics
|
October 29, 2010
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
E I Heath, E G Chiorean, C J Sweeney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
R Kurzrock, D W Bowles, H Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
W Xie, P Ravi, M Buyse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A A Hamid, H-C Huang, V Wang, et al.
Prostate Cancer and Prostatic Diseases
|
July 2, 2014
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act
B A Mahal, A A Aizer, D R Ziehr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
A Tripathi, Y Chen, D F Jarrard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
B A Mahal, Y-W Chen, V Muralidhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D J Jonker, L S Rosen, M B Sawyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2018
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
C L Vale, D J Fisher, I R White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
H-M Lin, T Scheinberg, N Portman, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Clinical Pharmacology and Therapeutics
|
October 29, 2010
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
E I Heath, E G Chiorean, C J Sweeney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
R Kurzrock, D W Bowles, H Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
W Xie, P Ravi, M Buyse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A A Hamid, H-C Huang, V Wang, et al.
Prostate Cancer and Prostatic Diseases
|
July 2, 2014
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act
B A Mahal, A A Aizer, D R Ziehr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
A Tripathi, Y Chen, D F Jarrard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
B A Mahal, Y-W Chen, V Muralidhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D J Jonker, L S Rosen, M B Sawyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2018
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
C L Vale, D J Fisher, I R White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
H-M Lin, T Scheinberg, N Portman, et al.
Page
of 5